Innovative Transdermal Technologies
Transcript of Innovative Transdermal Technologies
Innovative Transdermal Technologies
Table of Contents
1Com
pany
Hist
ory &
Org
aniza
tion
3AVERSA
4Pub
lic P
rofile
NTRB
Subsid
iaries
and
Cap
abilit
ies
2
2
Company History & OrganizationCreating Products to meet the needs of
Physicians, Patients and Payers (the 4 P’s)
1
Company Timeline
2012Nutriband Ltd. Founded inDublin, Ireland
Research conducted on Transdermal technologies in healthcare and pharmaceutical space. Business plan developed.
2012-2015
2016Nutriband Inc.established in Orlando,FL. Acquires NutribandLtd. (Ireland)
2018
2020Nutriband Inc.’s Abuse Deterrent Patent filed by its subsidiary 4P Therapeutics not granted and issued in Europe, UK, Japan, Korea, Australia, Russia, Mexico with prosecution continuing in US, Canada and China.
Nutriband Inc. Acquires 4P Therapeutics for $1.9MM paid in Company Stock and Cash. 4P Therapeutics Abuse Deterrent technology becomes the Lead product in Nutriband Inc.’s pipeline
2016Nutriband Inc. files Form10 with SEC, lists on OTCmarket.
2020
December – Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device
2020Nutriband Inc. acquires Pocono Coated Products Topical Transdermal manufacturing Division and Active Intelligence LLC for $7.5MM in Company Stock and Cash. Pocono Pharmaceuticals established as a subsidiary.
2021
Organizational Chart
CEO: Gareth SheridanCore Objective: Develop a transdermal abuse deterrent technology for Fentanyl patches, called AVERSA. With FDA approval AVERSA will revolutionize the safety standard for opioid based medications and save countless lives per year. Follow on projects include transdermal delivery of peptides and proteins targeting the Diabetes market
Core Objective: 4P Therapeutics is a clinical subsidiary of Nutriband Inc. (NTRB) focused on the research and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians and payers.
Core Objective: Leverage our existing transdermal technology to bring new & innovative products to the market.
Division Head: Dr. Alan Smith
Division Head: Tyler Overk
Division Head: Michael Myer
Core Objective: Ensure the delivery of tailored topical/transdermal products and solutions designed to meet our partners needs.
Capabilities● Contract Manufacturing
(Pocono)
● Testing and Release (Pocono)
● Quality Systems (Pocono / 4P)
● R&D / Clinical Development
● Nutriband Core Pipeline
2
460,000,000+
9
Topical / Transdermal Patches Manufactured to Date
Average annual growth rate of 60% (2018-2021)
Manufacturing
1MM Patches1.25”x1.25” patch
10
Over 250,000 Kinesiology Tape Strips 2”x10” (12,500 rolls w/20 strips)
Larger patch daily output is over 450,000 (3”x5”)
Daily Coating Capacity
Research & Development4P Therapeutics:The company has capabilities for developingpharmaceutical products from pre-clinical testingto clinical manufacturing and early stage clinicaldevelopment (Phase I/II). A key company focus andarea of expertise is in the development oftransdermal products for currently injectedcompounds, including proteins, peptides,macromolecules and biologics. Transdermaldelivery of commercially available drugs or biologicsthat are typically delivered via injection has thepotential to improve safety, efficacy andtherapeutic outcomes associated with thesetreatments
Core Prescription Pipeline
Exenatide● Dermal ablation
technology to deliver peptides.
● Indication for type 2Diabetes.
AVERSA®:● Abuse Deterrent
technology for opioid based medications
● Chonic Pain● TDS Delivery● Model to be proven
with Fentanyl market.● Applications range to all
potentially harmful orabusable Trandsdermaland topical medications.
FSH● Dermal ablation technology
applied to FSH for injection free delivery.
● Indication for Fertilitytreatment
AVERSA overview3
Public Profile NTRB
4
Stock symbol: NTRBTrading Market: OTCQB
As of Feb 8, 2021
Partners and Customers Served
16
NTRB Locations
Transdermal Patches/ partners / customers